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Abstract  16 
Autophagy is a highly conserved intracellular recycling pathway that serves to recycle damaged 17 
organelles / proteins or superfluous nutrients during times of nutritional stress to provide energy to 18 
maintain intracellular homeostasis and sustain core metabolic functions. Under these conditions, 19 
autophagy functions as a cell survival mechanism but impairment of this pathway can lead to pro-20 
death stimuli. Due to their role in synthesising and secreting insulin, pancreatic β-cells have a high 21 
requirement for robust degradation pathways. Recent research suggests that functional autophagy 22 
is required to maintain β-cell survival and function in response to high fat diet suggesting a pro-23 
survival role. However, a role for autophagy has also been implicated in the pathogenesis of type 2 24 
diabetes. Thus, the pro-survival vs pro-death role of autophagy in regulating β-cell mass requires 25 
discussion. Emerging evidence suggests that Glucagon-Like Peptide-1 (GLP-1) may exert beneficial 26 
effects on glucose homeostasis via autophagy-dependent pathways both in pancreatic β-cells and in 27 
other cell types. The aim of the current review is to: i) summarise the literature surrounding β-cell 28 
autophagy and its pro-death vs pro-survival role in regulating β-cell mass; ii) review the literature 29 
describing the impact of GLP-1 on β-cell autophagy and in other cell types; iii) discuss the underlying 30 
mechanisms. 31 
 32 
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protein 1 light chain 3 beta; LMP: lysosomal membrane permeabilization; 3-MA: 3-methyladenine; 9 
MCOLN1: mucolipin 1; mRFP: monomeric red fluorescent protein; mLST8: mTOR associated protein 10 
subunit LST8; mTORC1: mammalian target of rapamycin (mTORC1); PI3P: phosphatidylinositol 3-11 
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1. Introduction 1 
Macroautophagy (hereafter referred to as autophagy) is a highly conserved intracellular recycling 2 
pathway which targets cytosolic components for lysosomal degradation. Classically considered an 3 
essential mechanism to promote cell survival during nutrient deprivation, recycling of damaged 4 
organelles / proteins via autophagy releases nutrients and metabolites for energy production and 5 
biosynthesis to maintain cellular function and promote cell survival [1,2]. Under basal conditions 6 
when adequate nutrients are available, autophagy is inhibited although some constitutive activity 7 
remains to maintain basic cell function, removing unwanted proteins, organelles and foreign matter 8 
[3]. Autophagy can also be stimulated in response to nutrient excess to remove toxic aggregates or 9 
in response to increased protein synthesis to remove unfolded proteins, again to promote cell 10 
survival [1-4]. Thus, autophagy is primarily a cell survival mechanism acting to promote cellular 11 
homeostasis [4]. However, when exacerbated for long periods or when deregulated, autophagy can 12 
promote cell death. Hence, autophagy has been described as the ‘double-edged sword’ with the 13 
ability to switch from a pro-survival to pro-death role depending on the cellular environment [1-4].  14 
 15 
2. Molecular mechanism of autophagy 16 
The degradation of cytosolic components via autophagy involves complex signalling pathways with 17 
the interplay of more than 30 autophagy-related (Atg) proteins which are summarised below (Figure 18 
1). For a comprehensive review of these pathways readers are directed to [1,5,6].  19 
 20 
Autophagy is characterised by the formation of autophagosomes which surround and capture 21 
cytosolic components destined for recycling and their subsequent fusion with lysosomes to promote 22 
degradation and recycling of the contents [1-4]. It can be divided into four main stages: Initiation, 23 
Nucleation, Elongation / Completion, and Fusion / Degradation.  24 
 25 
i) Initiation: This stage is dependent on the activation state of Uncoordinated (Unc)-51-like kinase 1 26 
or 2 (ULK-1/2) which is regulated by mammalian target of rapamycin (mTORC1) and 5’ AMP-27 
activated protein kinase (AMPK). Starvation causes activation of ULK-1/2 via the activation of AMPK 28 
either through inactivation of mTORC1 or directly [7,8]. Under these conditions, autophagy is 29 
initiated.  30 
 31 
ii) Nucleation: Activation of ULK-1/2 in turn activates the class III phosphatidylinositol 3-kinase 32 
(PtdIns3K) complex consisting of Beclin 1, Vsp15, Vsp34, Atg14L and Ambra1, which is critical for 33 
formation of the phagophore via the localisation of phosphatidylinositol 3-phosphate (PI3P) and 34 
subsequent recruitment of key proteins [9,10].   35 
 36 
iii) Elongation / Completion: Once formed, the phagophore is elongated to generate the 37 
autophagosome which encaptures the cargo targeted for degradation. This stage is dependent on 38 
two ubiquitin-like degradation systems Atg16L1-Atg5-Atg12 and phosphatidylethanolamine (PE)-39 
LC3, in addition to the PtdIns3K complex to mediate localisation of key proteins such as LC3-PE to 40 
the expanding phagophore membrane [9,11-13].  41 
 42 
iv) Fusion / Degradation: Fusion of the closed autophagosome with lysosomes to form the 43 
autolysosome is dependent on several proteins including homotypic fusion and vacuole protein 44 
sorting (HOPS) complex, syntaxin 17 and lysosome-associated membrane glycoprotein-2 (LAMP-2). 45 
Following fusion, lysosomal enzymes are activated resulting in degradation of the contents to 46 
generate nutrients and metabolites which can be used as building blocks to promote cell survival 47 
[13-15]. 48 
 49 
The pathway outlined above assumes continuous flux through the pathway whereby the contents 50 
marked for degradation meet their end. However, if flux through the pathway is blocked due to loss 51 
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of fusion between autophagosomes and lysosomes, this impairment in autophagic signalling can 1 
contribute to cell death either via autophagic cell death or by stimulation of other cell death 2 
pathways [4,16]. Whether the impairment in flux occurs due to alterations in autophagosomal / 3 
lysosomal structures or to changes in signalling varies depending on the stimuli and cell type, and in 4 
many instances the underlying cause remains unknown.  5 
 6 
3. Technical approaches for monitoring of autophagy 7 
To understand how autophagy is regulated, one must first understand how it’s highly dynamic 8 
nature is evaluated. Comprehensive guidelines have been published [17] and the commonly used 9 
accepted measures are outlined below.  10 
i) LC3 lipidation – Lipidation of LC3-I to LC3-II is easily identified as distinct bands via western blotting 11 
and is regarded as a marker of increased autophagosomal content. However, an increase in LC3 II 12 
can result from both increased autophagy but also due to decreased autophagosomal clearance. 13 
Assessing LC3 I-II conversion in the absence or presence of lysosomal inhibitors (such as chloroquine 14 
or bafilomycin A1) provides some detail on flux [18,19]. 15 
ii) GFP-LC3 localisation to autophagosomes – Localisation of exogenously expressed GFP-LC3 to 16 
autophagosomes can be detected by a punctate pattern using fluorescence microscopy. Detail on 17 
flux can be provided using lysosomal inhibitors [19,20].  18 
iii) Tandem mRFP/mCherry-GFP LC3 – this technique is specifically designed to measure autophagic 19 
flux and is based on the pH differences between the neutral autophagosome and acidic 20 
autolysosome and pH sensitivity of GFP (sensitive) and mRFP / mCherry (stable). A red signal alone 21 
indicates increased autophagic flux whilst colocalisation of green and red signals indicate a blockage. 22 
This technique is deemed the most appropriate to monitor flux in vitro [21]. 23 
iv) Accumulation of p62 – The prototypic autophagic receptor p62 can be used as a measure of 24 
autophagic degradation since it is incorporated into autophagosomes and degraded in 25 
autolysosomes. In most tissues, activation of autophagic flux decreases p62 due to its continued 26 
degradation whilst accumulation of p62 is indicative of an impairment in flux [22,23].  27 
v) Transmission electron microscopy – this approach allows for visualisation of autophagic structures 28 
in relation to other cellular structures in isolated tissues. It is often used to determine the effect of 29 
stresses / disease on the autophagic pathway but lacks detail on autophagic flux [24,25].  30 
 31 
4. Autophagy in pancreatic β-cells 32 
 33 
4.1. β-cell autophagy under basal conditions 34 
Owing to their high requirements for insulin synthesis, granule formation and insulin release, 35 
pancreatic β-cells require robust degradation mechanisms to remove excess insulin and other 36 
granule components to maintain normal function and survival [26]. Early studies identified 37 
crinophagy (direct fusion of insulin granules with lysosomes) as a mechanism for regulation of insulin 38 
stores [27] but latterly, evidence supports a role for autophagy. Autophagy was reported to be 39 
pivitol to the regulation of proinsulin content in β-cells [28] and to the degradation of excess insulin 40 
in a mouse model of impaired insulin secretory capacity [29]. Further to this, β-cell specific genetic 41 
ablation of the key autophagic protein Atg7 caused accumulation of polyubiquinated proteins and 42 
damaged organelles when mice were fed a normal diet (16-20wks) [30,31]. These changes were 43 
associated with impaired glucose tolerance, decreased glucose-induced insulin secretion [30,31] and 44 
also loss of β-cell mass as a consequence of both increased apoptosis and decreased proliferation 45 
[30]. These studies support a role for autophagy in regulating β-cell physiology and survival. 46 
 47 
4.2. β-cell autophagy in response to nutrient excess 48 
A role for autophagy in the pathogenesis of type 2 diabetes has also been studied using high fat diet 49 
(HFD) or nutrient excess as models of type 2 diabetes. β-cell specific Atg7 -/- mice showed severe 50 
glucose intolerance when exposed to a HFD for 12 weeks [31]. When compared to wild-type animals, 51 
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the Atg7-/- mice had a decreased β-cell mass suggesting that autophagy is essential for the 1 
compensatory increase in β-cell mass in response to HFD [31]. This hypothesis is supported by 2 
numerous studies on in vitro β-cell models which showed that excess free fatty acids (FFA) or 3 
glucose increased autophagy [32-40], with reports of increased autophagic flux via the use of 4 
lysosomal inhibitors [32-35]. Furthermore, an increase in autophagic flux in response to HFD was 5 
shown in vivo using a mouse model overexpressing GFP-LC3 [41]. Similar to the results in the Atg7-/- 6 
mice, chemical or genetic blockage of autophagy increased β-cell death [32,33,40,41]. These studies 7 
support a protective role for autophagy in regulating β-cell mass in response to excess nutrients. 8 
 9 
However, several studies have shown that tissue from patients with type 2 diabetes show evidence 10 
of deregulated autophagy as evidenced by vacuole overload accompanied by increased 11 
autophagosomes [42] and also increased accumulation of p62, a marker of deregulated autophagy 12 
[43,44], indicating that autophagy may be impaired in type 2 diabetes. Similar findings were evident 13 
in animal models [43,45,45]. Studies on β-cell lines and isolated islets showed that although excess 14 
FFA initially stimulated autophagic flux, upon sustained exposure, flux was impaired as evidenced by 15 
accumulation of p62 and ubiquitinated proteins, decreased protein degradation and loss of 16 
autophagosomal-lysosomal co-localisation representing loss of fusion [44, 47-50]. Pharmacological 17 
stimulation of autophagic flux with rapamycin or carbamazepine caused clearance of accumulated 18 
autophagosomes and an improvement in cell survival [47-49,51] suggesting that the blockage in 19 
autophagic flux promoted cell death. 20 
 21 
To further investigate this conflicting evidence, we studied autophagic flux in β-cells exposed to 22 
excess FFA and high glucose using tandem mCherry-GFP LC3, a system considered the most robust 23 
for determination of autophagic flux [17,21]. Using this technique alongside other measures, we 24 
showed that nutrient excess does activate autophagy but if sustained causes deregulation of flux 25 
[44]. This promotes the accumulation of irregular, large autophagosomes and also enlarged 26 
lysosomes with impaired function. This is consistent with previous studies showing that FFA causes 27 
lysosomal dysfunction as evident by increased lysosomal pH and decreased cathepsin activity 28 
[47,48,52]. We were also able to show how this deregulation directly led to cell death via the loss of 29 
lysosomal membrane integrity and release of lysosomal contents into cytoplasmic compartments 30 
[44], a process known as lysosomal membrane permeabilisation (LMP) [53]. A role for this 31 
mechanism in fuelling nutrient excess-induced cell death was supported by the inhibition of cell 32 
death by a cathepsin D inhibitor. These studies thus suggest that it is dysregulation of the lysosomal 33 
compartment that fuels cell death, similar to that described in the renal tubule and neuronal cortex 34 
[54,55].  This is consistent with recent studies showing that treatment of lipid overloaded β-cells 35 
with photoactivatable acidifying nanoparticles were able to restore lysosomal pH and function, and 36 
improve glucose-induced insulin secretion [52] whilst exogenous overexpression of the lysosomal 37 
transcription factor EB (Tfeb) [56] to promote lysosomal biogenesis prevented FFA-induced β-cell 38 
death [46].  39 
We can therefore conclude that β-cell autophagy is essential for the maintenance of β-cell function / 40 
mass where it plays a pro-survival role. However, upon prolonged exposure to nutrient excess, this 41 
system becomes overloaded leading to deregulation of autophagic flux and accumulation of 42 
dysregulated lysosomes which play a pro-death role (Figure 2).  Whilst the activation of autophagy 43 
has been proposed to be via the AKT/mTORC1 axis, downstream of endoplasmic reticulum (ER) 44 
stress and involve JNK activation [33,36,38,44], the mechanisms underlying the loss of 45 
autophagosomal-lysosomal fusion is not clear. Pharmacological inhibition of ER stress reversed the 46 
FFA-induced defect in lysosomal function [44] supporting a role for ER stress in preventing fusion. 47 
Lipid incorporation into autophagic / lysosomal membranes has also been shown to dictate 48 
autophagosomal-lysosomal fusion [57]. Treatment of INS-1E with FFA altered the lipid composition 49 
of intracellular membranes which was associated with decreased autophagosomal-lysosomal fusion 50 
[50]. This was further exacerbated upon inhibition of stearoyl-CoA desaturase, an enzyme involved 51 
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in desaturation of fatty acids, supporting a role for lipid incorporation in regulating fusion. 1 
Interestingly, studies on transgenic mice expressing human Islet Amyloid Polypeptide (IAPP) showed 2 
that degradation of hIAPP by autophagy was essential for β-cell survival and that upon inhibition of 3 
autophagy, hIAPP accumulated leading to decreased β-cell mass in response to a HFD [58,59], thus 4 
suggesting that hIAPP may contribute to autophagic-dependent cell death. Further work is required 5 
to clearly identify the mechanisms involved. 6 
 7 
5. Impact of GLP-1 signalling on autophagy 8 
Glucagon-Like Peptide-1 (GLP-1) is released from intestinal L-cells in response to food intake and 9 
acts on multiple tissues to lower blood glucose [60]. This has resulted in the development of GLP-1 10 
receptor agonists (such as exenatide, liraglutide) and dipeptidyl peptidase-4 (DDP4) inhibitors (such 11 
as sitagliptin), which prevent the rapid degradation of endogenous GLP-1, for the treatment of type 12 
2 diabetes [61]. Despite their application in the clinic, the mechanisms by which these drugs exert 13 
their glucose-lowering effects are not well defined. In pancreatic β-cells GLP-1 acts to enhance 14 
glucose-stimulated insulin secretion and has also been shown to increase β-cell mass via increased 15 
proliferation and decreased apoptosis [62]. Recent studies have implicated a role for GLP-1 in the 16 
regulation of cell survival via alterations in autophagic signalling in both pancreatic β-cells (Table 1) 17 
and in other cell types (Table 2).   18 
 19 
5.1. β-cell autophagy 20 
Under basal, unstressed conditions GLP-1 receptor agonists did not alter β-cell autophagy [44,63,64]. 21 
In contrast, when β-cell autophagy was deregulated by chronic exposure to nutrient excess (FFA, 22 
high glucose), co-treatment with GLP-1 receptor agonists further stimulated autophagy as 23 
determined by increased LC3 II [44,63,64]. Further analysis in our laboratory using the mCherry-GFP-24 
LC3 system, showed that this increase was due to increased autophagic flux, consistent with the 25 
decrease in p62 accumulation [44]. This is supported by an in vivo model of HFD that showed that 26 
treatment with the DPP4 inhibitor MK-626 increased LC3 II and decreased p62 accumulation [65]. 27 
Chemical or genetic blockage of autophagy in β-cell models or in vivo partially prevented the GLP-1-28 
induced protection over β-cell survival or function [44,64,65] suggesting that stimulation of 29 
autophagic flux by GLP-1 is critical for its protective effects over FFA-induced β-cell dysfunction / 30 
death. Autophagic-independent mechanisms may also be at play since exendin-4 improved β-cell 31 
function and survival in β-cell specific Atg7 -/- mice [43]. However, it should be noted that this study 32 
was performed in the absence of nutrient excess in a setting where GLP-1 does not promote 33 
autophagy [44,64,64]. Feeding these β-cell specific autophagy deficient mice a HFD to recapitulate 34 
the stresses described above would firmly establish the importance of autophagy in the protective 35 
role of GLP-1 over β-cell function and survival. 36 
 37 
In addition to the stimulation of autophagic pathways, exendin-4 also improved autophagic flux by 38 
preventing the impairment in lysosomal function caused by FFA treatment which was associated 39 
with an increase in co-localisation between autophagosomes and lysosomes indicating increased 40 
autophagosomal-lysosomal fusion [44]. This is consistent with an independent study on tacrolimus-41 
induced diabetes which showed that exendin-4 improved lysosomal function and restored the 42 
impairment in fusion [66]. Restoration of autophagosomal-lysosomal fusion was essential for the 43 
protective effects of exendin-4 in this model since chemical inhibition of fusion using bafilomycin A1 44 
prevented the protective effect of exendin-4 over apoptosis [66]. These studies highlight the 45 
importance of lysosomal function in preserving β-cell survival and show that GLP-1 acts via 46 
restoration of this pathway to protect β-cells from insult. Interestingly, in tacrolimus-induced 47 
diabetes, exendin-4 did not stimulate autophagy [66] unlike in FFA treated β-cells which showed an 48 
increase in LC3 II and puncta formation [44,63-65]. Similarly, in a model of high fructose feeding, 49 
treatment with exendin-4 or sitagliptin decreased LC3 II levels suggestive of inhibition of β-cell 50 
autophagy which in turn improved β-cell function and mass [67]. Thus, the effectiveness of GLP-1 in 51 
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activating autophagy and / or promoting clearance of autophagosomes by improvement in 1 
lysosomal function may be dependent on the underlying mechanism of stress.  2 
 3 
5.2. non-β-cell autophagy 4 
Consistent with the studies in β-cells, the impact of GLP-1 on autophagy in other cell types appears 5 
to be specific to the underlying stress. In conditions of nutrient excess or in models of type 2 6 
diabetes, GLP-1 stimulates autophagy in a wide range of cell types which serves to improve cell 7 
function and survival. Studies in liver showed that GLP-1 receptor agonists increase autophagic flux 8 
in both rodents exposed to HFD and hepatocytes treated with FFA, which was associated with 9 
decreased steatosis and improved survival [68-72]. Furthermore, Roux-en-Y gastric bypass in 10 
diabetic mice increased liver autophagy which was deemed to be secondary to the increase in GLP-1 11 
release [73]. Studies in neurones isolated from type 2 diabetic mice showed that exendin-4 also 12 
stimulates autophagy in this cell type and that this effect is pro-survival [74], similar to the 13 
cardioprotective effects of exenatide and improved endothelial function with sitagliptin in animal 14 
models of diabetes via an autophagy-dependent mechanism [75-77]. Further to this, GLP-1 receptor 15 
agonists also increased autophagy in neurons from animal models of Parkinson’s disease and spinal 16 
injury [78,79] as well as in cardiomyocytes following treatment with the chemotherapy drug 17 
doxorubicin [80], which conferred protection from cell death.  18 
In contrast, GLP-1 agonists can also inhibit autophagy. In hepatocytes injured by ischaemia in the 19 
presence of HFD, exendin-4 decreased autophagy which was associated with an improvement in 20 
hepatocyte survival [71]. This suggests that in this hepatic ischaemic environment, autophagy plays a 21 
pro-death role and its inhibition by exendin-4 protects from cell death. Similarly, studies in retinal 22 
ganglion cells treated with H2O2 to increase oxidative stress showed that treatment with liraglutide 23 
decreased autophagy which lead to an improvement in cell survival [81]. Liraglutide also inhibited 24 
autophagy in the kidney tubule epithelium when exposed to high glucose which prevented cell death 25 
[82].  26 
In all the studies detailed above, whether GLP-1 receptor agonists promoted autophagy or inhibited, 27 
the overall impact of GLP-1 signalling was a pro-survival response. However, studies in pancreatic 28 
exocrine tissue highlight a potentially detrimental effect of GLP-1 which have been associated with 29 
an increase in autophagy. Chronic treatment of mice with both exenatide and sitagliptin caused 30 
spontaneous changes to the exocrine pancreas including inflammation, atrophy, apoptosis and 31 
autophagy, changes that were consistent with acute pancreatitis [83,84]. Further analysis revealed 32 
activation of pancreatic acinar autophagy associated with increased p62 accumulation, indicating 33 
impairment of flux [85]. However, a causative link between GLP-1 induced autophagy and cell death 34 
/ dysfunction was not shown [82-84]. Furthermore, meta-analysis of observational studies from 35 
humans treated with GLP-1 receptor agonists or DPP4 inhibitors did not highlight an association with 36 
acute pancreatitis [86,87]. Clearly, further work is required to determine the impact of GLP-1 37 
regulated autophagy on survival in the exocrine pancreas.  38 
 39 
5.3. Mechanisms underlying GLP-1 regulated autophagy 40 
The mechanisms underlying the impact of GLP-1 receptor agonists on both autophagy and lysosomal 41 
function are not yet elucidated. Studies in non-β cells support a role for the AMPK / mTORC1 axis in 42 
the activation of autophagic flux, whereby mTORC1 activity is inhibited by GLP-1, leading to 43 
autophagic activation [73,74,77]. However, several studies in β-cells have shown that treatment with 44 
GLP-1 receptor agonists activate mTORC1 which in turn induces proliferation and prevents apoptosis 45 
[88-90]. Consistent with this, treatment of the INS-1E β-cell line with exendin-4 in the presence of 46 
FFA caused increased phosphorylation of mTORC1 and its downstream target S6 (Zummo, Arden, 47 
unpublished data), suggesting that exendin-4 does not stimulate autophagy via inhibition of mTORC1 48 
in β-cells. Similarly, autophagic activation via the JNK / Beclin1 axis is unlikely since numerous 49 
reports show that GLP-1 receptor agonists inhibit JNK signalling [91-93] and since exendin-4 50 
increased LC3 I-II conversion in the presence of a JNK inhibitor [44]. Autophagy can also be activated 51 
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directly via AMPK / ULK1 in an mTORC1-independent manner (Figure 1). Studies in non-β cells have 1 
shown that starvation stimulates autophagy via an increase in intracellular Ca2+ which activates 2 
Ca2+/calmodulin-dependent protein kinase kinase (CAMKK), leading to activation of the AMPK / ULK1 3 
axis [94-95]. This is important since GLP-1 receptor agonists increase intracellular Ca2+ in β-cells [96] 4 
and studies have shown that activation of CAMKK is central to GLP-1 regulated β-cell gene 5 
expression [97]. However, the impact of GLP-1 receptor agonists on AMPK signalling is contentious 6 
with reports of both increased AMPK activity and also inactivation of the pathway [88,98,99]. 7 
It may be that GLP-1 alters autophagic signalling via non-canonical pathways. Recent studies have 8 
uncovered a novel role for calcineurin in the regulation of autophagy and lysosomal biogenesis 9 
[100,101]. During starvation or in response to exercise, Ca2+ is released from the lysosome via 10 
mucolipin 1 (MCOLN1), a calcium channel located in the lysosomal membrane. This localised calcium 11 
spike activates calcineurin which promotes a direct interaction between calcineurin and Tfeb, 12 
leading to dephosphorylation of the transcription factor EB (Tfeb) and its subsequent translocation 13 
to the nucleus where it promotes transcription of genes involved in autophagosomal and lysosomal 14 
biogenesis [91]. In our study we showed that treatment of INS-1E with exendin-4 in the presence of 15 
FFA increased Tfeb translocation and downstream transcription of autophagosomal and lysosomal 16 
proteins although the underlying mechanism was not explored [44]. A role for calcineurin in 17 
regulating GLP-1-induced autophagy is supported by recent findings that GLP-1 mediates beta-cell 18 
proliferation via calcineurin signalling in human β-cells from juvenile donors [102] and also that 19 
exendin-4 failed to increase LC3 II in β-cell treated with tacrolimus, an inhibitor of calcineurin [66]. 20 
However, it should be noted that exendin-4 was able to improve lysosomal function and restore 21 
lysosomal clearance in the model of tacrolimus-induced diabetes [66] and was also able to improve 22 
β-cell survival in human islets treated with tacrolimus [103]. Clearly further work is required to 23 
determine a role for this pathway in GLP-1 regulated autophagy. 24 
The molecular mechanisms of autophagy and endoplasmic reticulum (ER) stress are heavily 25 
interlinked [104]. Several studies have reported that GLP-1 receptor agonists decrease ER stress 26 
[44,68,105,106] and resolution of ER stress appeared to be essential for both improved lysosomal 27 
function [44] and autophagic activation [33,38,44], supporting a role for this pathway in driving GLP-28 
1 induced changes in autophagy. However, the exact mechanisms at play remain undetermined.   29 
 30 
5.4. Future directions 31 
Several outstanding questions remain: i) Firstly, what is the mechanism underlying the defect in 32 
lysosomal function in models of T2D? Could this be due to alterations in lipid composition of the 33 
lysosomal membrane and could this be altered by manipulating lipid handling? Can targeting of 34 
lysosomes improve β-cell function in animal models of T2D? How does GLP-1 act on these 35 
mechanisms? ii) Secondly, what are the signalling pathways by which GLP-1 activates autophagy in 36 
β-cells? It is via canonical or non-canonical signalling? Is this common to other tissues or is it β-cell 37 
specific? iii) Thirdly, how essential is autophagy for the protective effects of GLP-1 over β-cell 38 
survival and function in models of diabetes? Are GLP-1 receptor agonists able to improve β-cell 39 
survival and function in a β-cell model of high fat diet with simultaneous autophagic knockdown? iv) 40 
Finally, What is the impact of GLP-1 on autophagy in exocrine tissue? Is there any evidence that GLP-41 
1 receptor agonists contribute to the development of pancreatitis in these studies? 42 
 43 
6. Conclusions 44 
There is increasing evidence for a role of deregulated autophagy in the pathogenesis of type 2 45 
diabetes through its impact on β-cell function and survival. These findings have led to the suggestion 46 
that pharmacological targeting of autophagic / lysosomal pathways should be explored for the 47 
treatment of type 2 diabetes. However, the complex interplay between autophagy promoting cell 48 
survival vs death in varying tissues in response to different stimuli, complicates the use of a common 49 
pathway targeted approach. Emerging evidence that GLP-1 can regulate autophagy and that through 50 
this mechanism can promote cell survival and improve cell function highlights a novel therapeutic 51 
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approach. Elucidation of the underlying signalling pathways / mechanisms involved in the regulation 1 
of autophagy by GLP-1 is essential to determine the impact of GLP-1 receptor agonists and DPP4 2 
inhibitors on β-cell autophagy and the consequences on other cell types. Understanding these 3 
pathways could identify alternative therapeutic targets to enhance β-cell autophagy in the absence 4 
of deleterious effects. This avenue of research thus offers an exciting approach for the treatment of 5 
type 2 diabetes. 6 
 7 
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Figure 1: Schematic outlining the main molecular mechanisms and signalling pathways regulating autophagy. Under fed conditions, nutrients, growth 
factors and insulin inhibit autophagy though the activation of mTORC1 via the class I phosphatidylinositol 3-kinase (PI3K) / AKT / TSC / Rheb pathway. 
Activation of mTORC1 causes its binding to ULK-1 or 2, preventing autophagy. During starvation, AMPK is activated which initiates autophagy by i) activation 
of TSC1/2 leading to activation of Rheb and inactivation of mTORC1 which dissociates from ULK-1/2; ii) direct inactivation of mTORC1; iii) direct activation of 
ULK-1/2. ULK-1/2 is localised to a complex comprised of ULK-1/2, Atg13, Atg101 and FIP200 and its activation marks the initiation of autophagy. The 
activated ULK-1/2 complex in turn activates the PtdIns3K complex consisting of Beclin1, Vsp15, Vsp34, Atg14L and Ambra1. The activated PtdIns3K complex 
translocates to the phagophore assembly site (PAS) where it generates PI3P to recruit PI3P binding proteins such as DFCP1 and WIPI2b to PIP3 enriched 
regions, proteins essential for phagophore formation. Beclin1 can also be activated directly by AMPK and also via the JNK pathway via disruption of the anti-
autophagic Bcl-2-Beclin1 complex. The elongation of autophagosomes is dependent on two ubiquitin-like degradation systems, Atg16L1-Atg5-Atg12 and 
phosphatidylethanolamine (PE)-LC3. Conjugation of Atg proteins to form the Atg-16L1-Atg5-Atg12 complex in the presence of additional Atg proteins 
mediates LC3-PE formation and its localisation to the expanding phagophore membrane. These processes mediate phagophore elongation to form the 
autophagosome. In addition to this, replacement of Atg14L with UVRAG in the PtdIns3K complex further promotes autophagosome formation. Fusion of 
the closed autophagosome with lysosomes to form the autolysosome is dependent on the lipid composition of their membranes and also several proteins 
including the HOPS complex, the autophagosomal-specific SNARE named syntaxin 17 and LAMP-2 although the precise mechanisms are yet to be identified.  
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Figure 2: Schematic summarising the autophagic response to nutrient excess in pancreatic β-cells. In the setting of insulin resistance and nutrient excess, 
the increased demand for insulin and increased circulating nutrients act on the β-cells to activate autophagic flux. This results in an increase in protein 
turnover and removal of ubiqutinated proteins and damaged organelles from the cytoplasmic compartment. This removal of toxic aggregates promotes cell 
survival. However, if these stimuli are sustained the autophagic pathway become deregulated. Whilst the excess nutrients continue to activate autophagy 
and promote formation of autophagosomes, these nutrients also cause damage to the lysosomes causing a decrease in lysosomal function. This leads to 
loss of fusion between autophagosomes and lysosomes, leading to an impairment in autophagic flux. In the absence of functional autophagy toxic 
aggregates and dysfunctional lysosomes accumulate, leading to cell death.  
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Stress Model Drug          Effect of GLP-1 receptor agonist / DPP-4 inhibitor Ref 
on autophagy on disorder 
None Atg7 -/- mice Exendin-4 No effect (Atg7 -/-) ↑ glucose homeostasis 
↓ apoptosis 
[43] 
FFA -/+ HG 
 
INS-1E, islets 
 
 
Exendin-4 ↑ LC3 II, ↓ p62 
↑ flux (tandem LC3) 
↑ lysosomal function 
↑ AP-lysosome fusion 
↑ viability 
↓ apoptosis 
inhibited by Atg7 -/- 
[44] 
 Ins-1 Liraglutide ↑ LC3 II, AVO’s 
 
↑ viability 
Inhibited by CHQ/3-MA 
[63,64] 
HFD C57BL/J6 mice  MK-626 ↑ LC3 II, Atg7, ↓ p62 ↑ glucose homeostasis 
↑ insulin 
Inhibited by CHQ 
[65] 
Diabetes ApolipoproteinE -/- mice 
HFD + STZ 
Liraglutide ↑ AVO’s ↑ glucose homeostasis 
↓ plasma lipids 
Inhibited by CHQ 
[64] 
Tacrolimus Sprague Dawley,  
INS-1 
Exendin-4 ↓ LC3 II, p62, Ub-proteins, AVO’s 
↑ lysosomal function 
↑AP-lysosomal fusion 
↑ glucose homeostasis 
↑ β-cell mass 
↓apoptosis 
[66] 
Excess fructose Wistar rats  
isolated islets  
 
Exendin-4 
Sitagliptin 
↓ LC3 II, AVO’s ↑ glucose homeostasis 
↑ β-cell mass 
↓ apoptosis 
[67] 
 
 
Table 1: Effect of GLP-1 receptor agonists/DPP-4 inhibitors on pancreatic β-cell autophagy 
AVO: autophagic vacuoles; AP: autophagosome; CHQ: chloroquine; FFA: free fatty acids, HFD: high fat diet; HG: high glucose; 3-MA: 3-methyladenine; STZ: streptozotocin; 
Ub: ubiquitinated proteins.  
GLP-1 receptor agonists: Exendin-4, Liraglutide. DPP-4 inhibitors: MK-626, sitagliptin. 
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Tissue Stress Model Drug                    Effect of GLP-1 receptor agonist / DPP-4 inhibitor Ref 
on autophagy on disorder 
Liver none HepG2 Liraglutide ↑ AVO’s ↓ viability, mimicked by rapa [107] 
 FFA Human hepatocytes  Exendin-4 
 
↑LC3 II, Beclin1, AVO’s  
↑ flux (LC3 II + Baf) 
↓ steatosis 
↑ viability 
[68] 
  L0-2  Liraglutide ↑ LC3 II, ↓p62 
↑ flux (LC3 II + Baf) 
↓ steatosis, inhibited by 3-MA [69,70] 
  HuH7  Exendin-4 
 
↑ LC3 II, p62, LC3 puncta 
↑ flux (LC3 II + Baf) 
↓ cytotoxicity [71] 
 HFD C57BL/J6 mice  Liraglutide ↑ LC3 II, Beclin1, ↓p62 
↑ flux (LC3 II + CHQ) 
↓ steatosis,  
↑ glc homeostasis 
[68,69,
72] 
 Diabetes Sprague Dawley rat  
HFD + STZ 
Roux-en-Y  
(↑GLP-1) 
↑ LC3 II, Atg7, Beclin1,  ↓ steatosis,  
↑ glc homeostasis 
[73] 
 Ischaemia  HuH7 + FFA Exendin-4 ↓ LC3 II, p62, Beclin1, Atg7, LC3 puncta ↓ cytotoxicity [71] 
  C57BL/J6 mice + HFD Exendin-4 ↓ LC3 II ↓ cytotoxicity  [71] 
Heart Diabetes Zucker Diabetic rat Liraglutide ↑ LC3 II, LC3 puncta, AVO’s, ↓ p62  ↑ heart function, inhibited by CHQ [75] 
  Rat cardiomyocytes Liraglutide ↑ LC3 II, LC3 puncta, ↓ p62  ↓ apoptosis, inhibited by CHQ [75] 
 Doxorubicin Cardiomyocytes  Exenatide ↑ LC3 II, Atg7, Atg5, Beclin1, LC3 puncta ↓ cell death, inhibited by Baf [80] 
  Sprague Dawley rats  Exenatide ↑ LC3 II, Beclin1, ↓ p62 ↓ apoptosis [80] 
Kidney High glucose HK-2 cell line  Liraglutide ↓ LC3 II, Beclin-1 ↑ viability [82] 
Neuronal Diabetes Goto-Kakizaki mice  Exendin-4 ↑ LC3 II, ↓p62 ↓cell death [74] 
 Parkinson’s  SD rat + 6-OHDA lesion DA-JC1 ↑ Beclin-1 ↑ neuronal function [78] 
 Spinal injury Sprague Dawley rat  Exendin-4 ↑ LC3 II, Beclin-1, LC3 puncta ↑ cell survival [79] 
 Oxidative 
stress  
SH-SY5Y + rotenone Liraglutide 
Exenatide 
↑ Atg7, Atg3 ↑ viability [108] 
  RGC-5 + H2O2 Liraglutide ↓ LC3 II, Beclin1, p62, LC3 puncta ↓ cell death, inhibited by rapa [81] 
Monocytes Obesity Human monocytes from 
lean vs obese  
Exendin-4 
(in vitro) 
↑ LC3 II in lean but not obese ↓ foam cell in lean 
↑ foam cell in obese 
[109] 
Endothelial  High glucose Rat EPC’s Sitagliptin ↑ LC3 II, LC3 puncta, ↓p62 ↑ function, survival, inhibited by 3-MA. [77] 
 Diabetes Zucker Diabetic rat Sitagliptin ↑ LC3 II, ↓p62 ↓ endothelial damage,  [76] 
Exocrine 
pancreas 
HFD C57BL/J6 mice  Exenatide, 
Sitagliptin 
↑ AVO morphology  ↑ apoptosis, ↑ necrosis [83,84] 
 Diabetes SD rats on HFHSD + STZ Exenatide ↑ LC3 II, p62 Β-cell atrophy, ↑ apoptosis [85] 
Table 2: Effect of GLP-1 receptor agonists/DPP-4 inhibitors on autophagy in other cell types. 
AVO: autophagic vacuoles; Baf: Bafilomycin; CHQ: chloroquine; EPC’s: endothelial progenitor cells; FFA: free fatty acids, glc: glucose; HFD: high fat diet; HFHSD: high fat high 
sugar diet; 6-OHDA: 6-hydroxydopamine, 3-MA: 3-methyladenine; rapa: rapamycin; SD rat: Sprague Dawley rat; STZ: streptozotocin.  
GLP-1 receptor agonists: Exendin-4, Exenatide, Liraglutide. DPP-4 inhibitors: sitagliptin. Dual GLP-1/GIP agonist: DA-JC1.  
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Unshaded rows: GLP-1-induced autophagy, pro-survival; light shaded bars: GLP-1-inhibited autophagy, pro-survival; dark shaded bars: GLP-1-induced autophagy, pro-
death. 
 
